$1,100,000 of SANOFI US SERVICES INC lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"340B: Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations - General; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; Issues related to HR 1 One Big Beautiful Bill; HR 830 (118th) HELP Copays Act; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5143 (118th) Vaccines Access Improvement Act; HR 5376: Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Out of Pocket Cap; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339 (118th): PBM Reform Act; S. 1375: HELP Copays Act; S. 1542 (118th) DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues. 340B; Medicare Negotiation, and Most Favored Nation. Supply Chain Issues; and Importation issues. Supply Chain issues; and Vaccine Injury Compensation Program. S. 43: Skinny Labels, Big Savings Act; S. 2276 ETHIC Act; and Intellectual Property. Insulin; Taxes- General Issues; Vaccine - General Issues; Pharmacy Benefits Managers (PBMs); and Type 1 Diabetes Screening."
You can find more data on corporate lobbying on Quiver Quantitative.
SNY Congressional Stock Trading
Members of Congress have traded $SNY stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SNY stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/04 and 1 sale worth up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
SNY Hedge Fund Activity
We have seen 329 institutional investors add shares of SNY stock to their portfolio, and 336 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS removed 8,354,084 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $394,312,764
- INVESCO LTD. removed 3,390,657 shares (-36.9%) from their portfolio in Q3 2025, for an estimated $160,039,010
- DODGE & COX removed 2,786,568 shares (-3.9%) from their portfolio in Q3 2025, for an estimated $131,526,009
- RAYMOND JAMES FINANCIAL INC removed 2,443,717 shares (-41.6%) from their portfolio in Q3 2025, for an estimated $115,343,442
- THRIVENT FINANCIAL FOR LUTHERANS added 2,079,366 shares (+1722.2%) to their portfolio in Q3 2025, for an estimated $98,146,075
- MILLENNIUM MANAGEMENT LLC added 1,319,379 shares (+1151.8%) to their portfolio in Q3 2025, for an estimated $62,274,688
- BNP PARIBAS FINANCIAL MARKETS added 859,246 shares (+422.1%) to their portfolio in Q3 2025, for an estimated $40,556,411
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SNY Analyst Ratings
Wall Street analysts have issued reports on $SNY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 10/27/2025
- Morgan Stanley issued a "Overweight" rating on 09/08/2025
- Deutsche Bank issued a "Buy" rating on 09/02/2025
To track analyst ratings and price targets for SNY, check out Quiver Quantitative's $SNY forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
